If you had bought Kiniksa Pharmaceuticals International on 13 November 2025 and simply sat tight, the outcome would look very different today. Investors who held Kiniksa Pharmaceuticals International over the past year are up 138.9%, including dividends. Early in that period, you were choosing between bullish calls built on ARCALYST penetration and pipeline progress, and cautious views focused on single-drug risk and payer pressure. Which side of that tradeoff would have guided your decision then?
The move put Kiniksa Pharmaceuticals International in the middle of this trade. Scan 36 healthcare AI stocks for other companies exposed to it.
The shares cost US$40.29 at the start of the period, and buyers had to decide which story about Kiniksa Pharmaceuticals International sounded more convincing.
The bullish narrative pointed to a Fair Value of US$47, a price implied by expectations of what the business could earn if things went right. This view was built on assumed 24.3% revenue growth and profit margins reaching 19.8% within about three years.
The cautious view anchored on a Fair Value of US$38, tied to assumptions of 21.0% revenue growth and margins rising to 14.4%. In this scenario, single drug reliance and payer pressure were treated as central risks.
Kiniksa Pharmaceuticals International reported Q3 2026 revenue of US$285.97 million and net income of US$47.35 million, with net margin at 16.6% versus 10.2% a year earlier. That uplift in both sales and profitability, paired with raised ARCALYST guidance and ongoing KPL-387 and KPL-1161 progress, supported the more optimistic case based on higher margins and pipeline execution.
The key issue was margin quality tied to a flagship therapy. When you assess another biotech built around one core drug, track net margin alongside product concentration in quarterly filings to see whether dependence is turning into earnings strength or rising risk.
Today, Kiniksa Pharmaceuticals International trades at US$96.33. The bullish analyst narrative on Simply Wall St sees fair value above that level, based on confidence in ARCALYST uptake and a broader IL‑1 portfolio around KPL‑387 and KPL‑1161.
Under that view, you would be judging whether the current price still underestimates how far ARCALYST reach and IL‑1 layering could reshape earnings power.
"The current valuation implies that the market is not fully pricing in ARCALYST guidance of US$980 to US$995 million net revenue for 2026, the recent share price rise of over 125% in a year, and rising institutional ownership, which together indicate expectations for materially higher earnings power than is reflected in prior views of the stock."
One Narrative disagrees with today's price. → See where this Narrative says Kiniksa Pharmaceuticals International should trade
Kiniksa puts immune and inflammatory disease in focus. You can stop there. Or look one step sideways.
Patients facing those conditions sometimes also manage cancer, viral infections or chronic liver damage.
Another large drug maker is targeting those related needs with specialty medicines, vaccines and newer liver therapies.
Its management is directing more research toward oncology, advanced vaccines and metabolic liver disease.
If that shift works, your watchlist might pair a focused Kiniksa story with a more diversified healthcare engine.
The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 54% above its price
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com